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The M-type phospholipase A2 receptor (PLA2R) is the major
target antigen in idiopathic membranous nephropathy with
detectable autoantibodies in the serum of up to 70% of
patients. In retrospective studies, the PLA2R-autoantibody
titer in the serum was sometimes negative indicating their
measurement alone may be inconclusive. In order to better
differentiate between primary and secondary membranous
nephropathy, we conducted a prospective study that
included 88 patients with a histologic diagnosis of
membranous nephropathy. Immunohistochemical analysis
for PLA2R was faintly positive in kidneys from normal
individuals and patients with various other glomerular
injuries. In 61 of the 88 patients, PLA2R expression was
strongly positive in glomeruli, and in 60 of these patients
PLA2R autoantibodies were also detected in the serum. The
27 patients negative for serum PLA2R autoantibodies were
faintly positive for PLA2R staining in glomeruli and in 15 of
these patients a secondary cause was found. The remaining
12 patients have a yet undetected secondary cause of
membranous nephropathy or have different glomerular
antigens other than PLA2R. Thus, increased staining for
PLA2R in glomeruli of renal biopsies tightly correlates with
the presence of PLA2R autoantibodies in the serum and this
may help discriminate between primary and secondary
membranous nephropathy.
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Membranous nephropathy (MN) is the leading cause of a
nephrotic syndrome in Caucasians. The disease is character-
ized by the presence of immune complexes in the
subepithelial space of the glomerular filtration barrier. An
in situ immune complex formation is considered to be the
pathogenetic mechanism, which means that circulating
antibodies bind to an antigen expressed on glomerular
podocytes.1,2 InB25% of patients, MN is associated with an
underlying disease, such as systemic lupus erythematodes,
malignant tumors, or disease caused by exposure to certain
drugs or due to a variety of viral or bacterial infections.3
When no secondary cause is apparent, the disease is classified
as primary. However, in some patients, MN can appear
months or even years before a secondary cause is detected.
In these patients, particularly those older than 65 years, great
uncertainty exists about the clinical management, as an
undetected malignant tumor could be the cause.4 Further-
more, in some patients, MN and a potential secondary cause
of MN (e.g., malignoma) may develop independently of each
other and present chronologically within a short period of
time.4,5 Hence, the differential diagnosis between primary
and secondary MN is of great clinical importance. In patients
with primary MN, a conservative or an immunosuppressive
treatment is chosen depending on the clinical status, whereas
in patients with secondary MN treatment is directed toward
the causal disease.6 A reliable differentiation between primary
and secondary MN would substantially improve further
management of the patients. This could include less
diagnostic procedures in the case of a primary MN or a
more aggressive diagnostic approach to search for underlying
causes in secondary forms of MN.
The discovery of the M-type phospholipase A2 receptor
(PLA2R) as a target antigen in primary MN
7 is an important
finding, which could help improve the differential diagnosis
of MN. In a series of retrospective analyses in patients
with biopsy-proven MN, the levels of PLA2R-antibodies
(PLA2R-AB) in the serum, however, ranged from 52 to
78%7–11 and demonstrated that there may be uncertainty in
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the differential diagnosis. The reported discrepancies in these
mostly retrospective studies might have several reasons: (i)
immunosuppression could have removed the antibodies;7–10
(ii) as in a large number of patients the measurement of
PLA2R-AB was performed after a long time interval following
renal biopsy, spontaneous remission with disappearance of
the antibody might have occurred; and (iii) antigens other
than the PLA2R may be relevant for MN. Thus, only a
prospective analysis in which the PLA2R-AB levels are
measured in close proximity to the time of renal biopsy will
help to obtain a near estimation of the real number of
PLA2R-AB-positive patients. Second, we hypothesized that
the intensity of the glomerular expression of the PLA2R could
be another parameter to increase the specificity of the
differential diagnosis between primary and secondary MN,
as antigen–antibody complexes should be present in active
disease.7 We therefore analyzed in this prospective study 88
patients with biopsy-proven MN for their PLA2R protein
expression in glomeruli and analyzed their PLA2R-AB serum
levels in close proximity to the time of biopsy. PLA2R
staining is enhanced in glomeruli of those patients in whom
antibodies are detectable in the serum and correlates with the
detection of PLA2R-AB in the serum. PLA2R-AB and PLA2R-
antigen were not found in patients with secondary MN. We
conclude that the increased glomerular PLA2R staining and
the detection of PLA2R-AB improve the differential diagnosis
between primary and secondary MN.
RESULTS
Baseline patients’ characteristics
Between November 2009 and April 2011, 88 consecutive
patients (64 men and 24 women) with the histologic
diagnosis of MN made in our institution were included in
this study (Supplemental Table S1 online). None of the
patients had received immunosuppressive therapy before the
renal biopsy or the measurement of PLA2R-AB levels. In 66
(75%) patients, serum PLA2R-AB was measured within 4
weeks after renal biopsy, in 16 (18%) patients between 4 and
24 weeks, and in the remaining 6 (7%) patients between 24
and 44 weeks following renal biopsy. At the time of PLA2R-
AB measurement, mean proteinuria was 8.0±5.7 g/24 h. All,
except three, patients were on angiotensin-converting enzyme
inhibitors or AT2-R blockers at the time of PLA2R-AB
measurement. In all, 66 (75%) patients received lipid-
lowering medications, and 69 (78%) patients were on
diuretics. Anticoagulation was initiated in 33 (37%) patients.
PLA2 receptor immunohistochemistry and PLA2 receptor
antibodies
Immunohistochemical staining for PLA2R revealed a faint
positivity in normal kidneys (see Figure 1a). PLA2R was
selectively expressed on podocytes in a fine granular pattern.
In 61 (69%) out of the 88 patients with the histologic
diagnosis of a MN, the immunohistochemistry revealed a
markedly enhanced glomerular staining for the PLA2R when
compared with the normal kidneys. Immunohistochemistry
showed a more granular pattern (Figure 1d). The immune
deposits are localized in the subepithelial space and appear in
the same location as the staining for immunoglobulins
(Figure 1e and h). The enhanced expression of the PLA2R was
very similar and homogeneous between the individual
patients and did not show any significant correlation with
the serum antibody levels or the degree of proteinuria. It
rather resembles an ‘on’–‘off ’ phenomenon.
When analyzed for the presence of PLA2R-AB in the serum,
antibodies were detectable in 60 (98.4%) of the 61 patients
with enhanced glomerular PLA2R (Figure 2). An enhanced
glomerular PLA2R staining was found in Patient 18, but no
PLA2R-AB was detected in his serum. PLA2R-AB measurement
in this case was performed 9 months after the renal biopsy. Of
the other 27 patients with the histologic diagnosis of MN who
did not reveal an enhanced PLA2R expression in glomeruli
(Figure 1g), and who had no detectable PLA2R-AB in the
serum (Figure 2), an underlying disease was detected in 15
patients. Five patients had systemic lupus erythematodes, one
patient had hepatitis B, seven patients had malignant tumors,
and two patients had developed MN while taking nonsteroidal
anti-inflammatory drugs.
There was no significant difference in all important
clinical parameters between patients with an enhanced
PLA2R expression and those without an enhanced PLA2R
expression in glomeruli (Table 1). Proteinuria and serum
creatinine levels were slightly higher in patients with
enhanced PLA2R expression in glomeruli, but these differ-
ences were not statistically significant.
To study whether the PLA2R expression was an exclusive
finding in PLA2R-AB-positive patients with MN, renal biopsies
of 78 patients with various diseases (14 with minimal change
disease, 11 with immunoglobulin IgA nephropathy, 9 with
primary FSGS, 8 with sarcoidosis, 8 with diabetic nephrop-
athy, 7 with lupus nephritis type IV, 6 with lupus nephritis
type V, 6 with MPGN type I, 4 with fibrillary GN, and 5
normal kidneys) were tested for the expression of the PLA2R
and the presence of PLA2R-AB in the serum. PLA2R expres-
sion in all renal biopsies from patients with diseases other
than MN was similar to the expression in glomeruli of normal
kidneys or in kidneys from patients with secondary MN (data
not shown). None of the patients with renal diseases other
than MN had detectable PLA2R-AB in the serum.
Characterization of PLA2R-AB subtypes in the serum
In all PLA2R-AB-positive patients, IgG4-PLA2R-AB levels
were detectable. In addition, in 80% (48 of 60 patients) of
these patients other PLA2R-AB IgG subtypes were detectable
(Table 2). In 20% (12 of 60 patients), the IgG4 subclass
PLA2R-AB was the only detectable antibody, whereas in 40%
(24 of 60) all IgG subclasses of PLA2R-AB were present.
Correlation between proteinuria and PLA2R-AB levels
When an analysis was performed to check whether protein-
uria and PLA2R-AB levels show a potential interrelation and
whether PLA2R-AB levels eventually indicate the severity
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of the clinical disease at the time of the measurement of pro-
teinuria, no correlation could be detected by the Spearman’s
rank coefficient of correlation (r¼0.06; P¼ 0.65; Figure 3).
In vitro analysis of the specificity of the antibody applied for
immunohistochemistry
As one would assume, in the in vivo situation, when PLA2R-
AB levels are detectable in the serum of the patients, all
epitopes of the receptor would be occupied by the circulating
antibodies. It was therefore surprising that in the in vitro
situation of the immunohistochemical analysis of the renal
biopsies from patients with PLA2R-AB in their serum an
antibody could still detect the increased PLA2R in the
glomeruli. We therefore tested in an in vitro approach, using
PLA2R-overexpressing HEK 293 cells, whether human
PLA2R-AB from serum was able to impair, or even abolish,
the binding of the diagnostic antibody against PLA2R used
for immunohistochemistry. Antiserum from patients with a
high titer of the PLA2R bound to a receptor on the cells but
did not interfere with the binding of the diagnostic antibody
applied for immunohistochemistry (Figure 4). This may
suggest that potentially pathogenetic human PLA2R-AB
bind to (an) epitope(s) other than the antibody used in the
immunohistochemistry.
Measurement of PLA2R-mRNA expression in renal tissue by
reverse transcription-PCR
To address the question whether the enhanced expression of
the PLA2R might be the result of an increased PLA2R
formation, we measured the mRNA expression of PLA2R in
kidneys from patients with MN and enhanced PLA2R
staining (n¼ 6) and kidneys from patients with MN and
no enhanced PLA2R staining (n¼ 6). As summarized in
Figure 5, there was no difference between the mRNA levels of
the PLA2R in the different groups (P¼ 0.53).
IgG4 staining of renal biopsies
When stained for IgG4, 95% (58 of 61) of renal biopsies from
patients with an enhanced PLA2R staining were positive
(Table 3). In contrast, only 20% (3 of 15) of patients with a
known secondary cause of MN had a positive IgG4 staining.
Furthermore, 45% (5 of 11) of patients who did not have an
enhanced PLA2R staining and in whom no secondary cause
of MN was detectable had a positive IgG4 staining.
PLA2R
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Figure 1 |Histology of the various forms of membranous nephropathy. Immunohistochemical staining (APAAP method; original
magnification  1.140) of phospholipase A2 receptor (PLA2R) and IgG1 and transmission electron microscopy (EM; original magnification
 7.000) of renal biopsies from a normal kidney (a–c), from a patient with primary membranous nephropathy (MN) (d–f), and from a patient
with secondary MN (g–i). The gallery shows that only PLA2R staining but not immunoglobulin G1 (IgG1) staining or EM allows to
differentiate between primary and secondary MN.
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DISCUSSION
This prospective study in patients with MN shows that
patients with MN who had an enhanced glomerular expres-
sion of the PLA2R by immunohistochemistry also had detectable
PLA2R-AB in their serum. In contrast, patients who did not
have enhanced glomerular PLA2R expression had no detectable
PLA2R-AB in their serum. Neither PLA2R-antigen in biopsy
nor PLA2R-AB in serum was found in patients with a known
cause of secondary MN. This observation allows separating
what is currently called primary MN from secondary MN.
It is of great clinical importance to discriminate between
patients with primary and secondary MN. Diagnostic
procedures and therapeutic strategies are completely different
for these patients. Although therapy of the secondary form is
directed to an underlying disease, in patients with primary
MN an immunosuppressive strategy may be an option.6 The
Enhanced Normal
61 Patients 27 Patients
60 Patients 1 Patient
PLA2R-AB in serum
PLA2R staining
Positive Negative
0 Patients 27 Patients
Positive Negative
0 Patients 0 Patients
Secondary cause of MN
0 Patients 15 Patients
Secondary cause of MN
SLE:
5 Patients
Tumor:
7 Patients
NSAID:
2 Patients
Hep. B:
1 Patient
No known cause 
of secondary MN:
12 Patients
PLA2R-AB in serum
Figure 2 | Sixty (98.4%) patients with enhanced glomerular phospholipase A2 receptor (PLA2R) staining had detectable PLA2R-
antibody (AB) levels in the serum. All patients with normal glomerular PLA2R staining had no PLA2R-AB in the serum. A secondary cause
of membranous nephropathy (MN) was found in 15 (56%) patients with normal glomerular PLA2R staining and no detectable PLA2R-AB
levels (5 patients with systemic lupus nephritis, 7 patients with a malignant tumor, 2 patients receiving nonsteroidal anti-inflammatory
drugs (NSAID), and 1 patient with hepatitis B (Hep. B)). In 12 patients with normal glomerular PLA2R staining and no titer of PLA2R-AB in the
serum, no secondary cause of MN could be identified. SLE, systemic lupus erythematodes.
Table 1 | Clinical characteristics of the patients included in this study. Patients with enhanced PLA2R staining did not
significantly differ in any of the clinical features from patients with normal PLA2R staining
Enhanced glomerular
PLA2R staining
Normal (non-enhanced)
glomerular PLA2R staining P-value
Number of patients 61 27 –
Age (mean±s.d.), years 56.5±15.8 57.7±15.0 0.74
Gender (m:f) 49:12 15:12 –
Serum creatinine, mg/dl (mean±s.d.) 1.4±0.8 1.2±0.5 0.19
Proteinuria, g/24 h (mean±s.d.) 8.6±6.1 6.7±4.6 0.15
Time from renal biopsy to PLA2R-AB measurement in serum, months (mean±s.d.) 1.6±2.8 1.7±2.5 0.94
Abbreviations: AB, antibody; f, female; m, male; PLA2R, phospholipase A2 receptor.
Table 2 | IgG subclasses of PLA2R-AB in patients with
detectable PLA2R-AB in serum. The data show that all
patients, who were positive for PLA2R-AB, had IgG4 subclass
antibodies. In a large percentage of patients, however, other
IgG subclass antibodies were present
PLA2R-AB subtypes in serum
Number of patients (% of PLA2R-AB
positive)
PLA2R-AB positive 60 (100)
IgG1 35 (58.3)
IgG2 29 (48.3)
IgG3 42 (70.0)
IgG4 60 (100)
Only one PLA2R-AB subtype
(IgG4)
12 (20.0)
Two PLA2R-AB-IgG subtypes 14 (23.3)
Three PLA2R-AB-IgG subtypes 10 (16.7)
All four PLA2R-AB-IgG subtypes 24 (40.0)
Abbreviations: Ig, immunoglobulin; PLA2R-AB, phospholipase A2 receptor antibody.
800 Kidney International (2012) 82, 797–804
or ig ina l a r t i c l e E Hoxha et al.: PLA2 receptor and membranous nephropathy
correct diagnosis is essential to avoid unnecessary drug
exposure or extensive diagnostic procedures. To date, the
diagnosis of primary MN is still made by exclusion of
secondary causes, using medical history, physical examina-
tion, appropriate laboratory tests, and often invasive
diagnostic procedures. A standardized diagnostic approach,
which could distinguish between primary and secondary
forms of MN, would therefore lead to a more focused
investigation of secondary causes only when necessary. This
would be particularly important in patients with MN over
65 years of age, as MN may be either associated or may be
detected years before a diagnosis of a malignant tumor.4,5
This study consists of the staining of renal biopsies from
patients with the diagnosis of MN for the PLA2R and the
concurrent measurement of PLA2R-AB in the serum. PLA2R-
AB levels are detected only in sera from patients with a
‘primary’ form of MN.7,9 Yet, not all patients with primary
MN show PLA2R-AB.
7,9 This discrepancy could be due to
spontaneous remission of the disease, immunosuppressive
therapy, or the existence of other antigens. To avoid the
possibility of spontaneous remission of proteinuria or
immunosuppressive therapy, we chose a prospective ap-
proach and tried to measure antibody levels as close as
possible to the time of renal biopsy. The mean time from
renal biopsy to antibody measurements was 1.6 months,
which is a very short time compared with all the published
retrospective studies.
With the use of a polyclonal PLA2R-AB, we were able to
show an enhanced expression in 61 out of 88 patients with
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Figure 3 | The figure summarizes the phospholipase A2
receptor-antibody (PLA2R-AB) levels in relation to the
proteinuria at the time of the first PLA2R-AB measurement.
There was no correlation between PLA2R-AB titers and
proteinuria.
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Figure 4 | Specification of the diagnostic antibody used for
PLA2R detection. The rabbit polyclonal phospholipase A2 receptor
(PLA2R) antibody (used for immunohistochemistry) binds to the
PLA2R in HEK 293 cells that were either preincubated with human
serum (containing human PLA2R-AB) (a) or not incubated with
serum (b). Detection with a fluorescein isothiocyanate (FITC)-
conjugated anti-rabbit IgG antibody from donkey shows the same
immunofluorescence intensity. FITC-conjugated anti-rabbit IgG
antibodies from donkey do not bind to human PLA2R-AB (c), and
thus the immunofluorescence that can be seen in a cannot be
attributed to the human serum containing PLA2R-AB. Human
PLA2R-AB from the human serum used in a bind to PLA2R, as
shown when detected with a FITC-conjugated anti-human IgG
antibody from goat (d).
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Figure 5 |The figure shows the expression of phospholipase
A2 receptor (PLA2R)-mRNA from whole kidney biopsies. The
relative expression of PLA2R-mRNA (podocin was used as
reference gene) was not different between patients with
enhanced and those with non-enhanced PLA2R staining.
NS, not significant.
Table 3 | Ninety-five percent of patients with enhanced PLA2R
staining had a positive IgG4 staining in renal biopsies. Only
31% of the patients with non-enhanced PLA2R staining had a
positive IgG4 staining
Enhanced PLA2R
staining
Non-enhanced
PLA2R staining
Number of patients 61 27
Number of patients with positive
IgG4 staining (%)
58 (95.0) 8 (30.8)a
Abbreviations: Ig, immunoglobulin; PLA2R, phospholipase A2 receptor.
aIn one case with non-enhanced PLA2R staining and no PLA2R-AB in serum, no IgG4
staining could be performed because of lack of further renal tissue.
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biopsy-proven MN, compared with only a faint expression in
normal kidneys. Immunohistochemistry showed a granular
pattern. The immune deposits are localized in the sub-
epithelial space, whereas in normal kidneys the antigen is
detectable only on the cell surface of the podocytes. The
intensity of the expression was similar in all biopsies that
were considered enhanced and has the characteristic of an
‘on’ or ‘off ’ situation. The staining intensity was independent
of the PLA2R-AB levels, which were very different in these
patients and did not show any correlation with the level of
proteinuria as well. A very similar observation of a histologic
pattern of ‘negative’ or ‘positive’ for PLA2R1 staining was
recently reported by others11 using immunofluorescence
histology. These investigators also did not report a difference
in the intensity of PLA2R staining in the presence of different
serum antibody levels. Thus, both studies might suggest that
there is a limit in receptor availability. To address this issue in
some more detail, the mRNA expression of the PLA2R was
studied. Renal biopsies from patients with MN and enhanced
PLA2R staining did not show increased transcription of the
receptor when compared with renal biopsies from patients
with MN but non-enhanced PLA2R staining. This of course
does not exclude the possibility of increased posttranscrip-
tional synthesis or any other mechanism that may increase
the availability of the antigen to the surface of the podocytes.
The results, however, do not support the findings in
experimental MN, in which it was shown that the receptor
synthesis is increased.12 To address these questions in more
detail, in vivo and in vitro studies are necessary.
To better understand, however, the finding that the
glomerular PLA2R expression by immunohistochemical
techniques is detectable in a situation in which excessive
circulating antibodies in these patients probably bind all
epitopes of the receptor, we performed additional in vitro
studies in HEK 293 cells overexpressing the PLA2R. These
in vitro experiments show that the naturally occurring
antibodies in the patients bind to (a) epitope(s) on the PLA2R
different from those epitopes which are bound by the
antibody that was used for the detection of the receptor in
the renal tissues.
In a next step, we wanted to be certain that PLA2R
expression is exclusive in patients with MN, as in other
studies PLA2R–AB were detected in patients with sarcoidosis,
systemic lupus erythematodes, or tumors.13,14 For this
purpose, 78 biopsies from patients with various glomerular
injuries other than MN were studied. In none of these
patients, including 8 patients with sarcoidosis and 13 patients
with systemic lupus erythematodes PLA2R-antigen, staining
was increased in glomeruli. The immunohistochemistry in all
of these biopsies shows the same pattern as in control kidneys
(data not shown).
As it has been demonstrated that the PLA2R-AB belongs
primarily to the IgG4 subclass,7 the renal tissues were stained
for the presence of IgG4 antibodies. Although the vast
majority of patients with enhanced PLA2R were positive for
IgG4 staining (95%), this was not the case for patients who
did not have an enhanced glomerular PLA2R staining. In
patients with a secondary MN and a known cause of the
disease, only 20% were positive for IgG4. In patients with
non-enhanced glomerular PLA2R staining and without a
known secondary cause of MN, in 45% of patients IgG4 was
detectable in glomeruli.
When the 61 patients with MN who had an enhanced
glomerular PLA2R expression were compared with those
patients who had detectable serum levels of the PLA2R-AB,
60 of the 61 patients did show both. It is currently unclear
why patient 18 did not have detectable PLA2R-AB, but this
patient might have been in immunologic remission with still
detectable enhanced PLA2R expression in his glomeruli.
If one accepts the hypothesis that primary MN is
characterized by the presence of PLA2R-AB
7 and adds the
information that these antibodies can become negative
for several reasons,7–10 then primary MN can be diagnosed
by the histologic pattern that we show in our study—that is,
an increased expression of the PLA2R in glomeruli in
combination with the standard morphologic diagnostics of
MN. This might be of clinical importance when the time of
biopsy is far (several months to years) from antibody
measurement.
Our data, however, also show that under the conditions
described in this manuscript a positive PLA2R-AB serum level
allows the diagnosis of primary MN and supports the initial
hypothesis of Beck et al.7 In all, 82% (60/73) of patients, in
whom no secondary cause of MN could be detected,
were positive for PLA2R-AB. This is the highest rate of
PLA2R-AB positivity shown in a Caucasian population. By
using a highly sensitive western blot approach in a Chinese
cohort, an even higher percentage of seropositivity for
PLA2R-AB was found.
14
The remaining 12 patients in our study in whom no
clinical cause was found and who were negative for PLA2R
and PLA2R-AB can currently only be classified as having
secondary MN. IgG4 positivity has been suggested as a
potential marker to differentiate primary from secondary
MN.15–18 In these 12 patients, however, only 45% showed
positivity for the IgG4 subclass in glomeruli.
If other antigen–antibody pairs are identified, which have
a role in the development of MN, the definition of primary
and secondary MN might be modified to add the informa-
tion of the antigen–antibody pair. Until this is clear, we
suggest that patients with either enhanced PLA2R in
glomeruli or elevated PLA2R-AB in the serum would have a
primary MN.
MATERIALS AND METHODS
Recruitment of patients
In this prospective study, 88 consecutive patients with the histologic
diagnosis MN were studied. Patients were eligible to participate if
the diagnosis of MN was confirmed by a renal biopsy and if they had
not received any immunosuppressive treatment before renal biopsy
and PLA2R-AB measurement. The study was conducted in
accordance with the ethical principles stated by the Declaration of
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Helsinki Principles. An informed consent was obtained from all
participating patients, and the study was approved by our local
ethics committee.
Diagnosis of MN
MN was diagnosed by renal biopsy at the Nierenregister Hamburg,
Universita¨tsklinikum Hamburg-Eppendorf (Hamburg, Germany).
Diagnosis was made on the basis of light microscopy, immunohis-
tochemistry, and electron microscopy findings (see Figure 1). All
patients underwent a screening for secondary causes of MN,
including a detailed medical history consisting of medication,
physical examination, serological analysis (i.e., for systemic lupus
erythematodes, hepatitis B, hepatitis C and HIV), and the exclusion
or presence of malignant diseases as intensive as possible.
PLA2R-AB measurement and renal biopsy staining
Measurement of PLA2R-AB and detection of subtype-specific IgG
antibodies in the serum were performed with an indirect immuno-
fluorescence test as described.9 For detection of subtype-specific
IgG antibodies, fluorescein isothiocyanate (FITC)-conjugated
monoclonal anti-human IgG1 (Sigma-Aldrich Chemie GmbH,
Mu¨nchen, Germany, product no. F0767), IgG2 (Sigma-Aldrich,
product no. F4516), IgG3 (Sigma-Aldrich, product no. F4641),
and IgG 4 (Sigma-Aldrich, product no. F9890) antibodies from
mouse were used.
In all patients, in addition to standard histology, kidney biopsies
were immunohistochemically stained with a rabbit polyclonal anti-
PLA2R–AB (Atlas Antibodies AB, Stockholm, Sweden). Staining for
PLA2R, IgG1, and IgG4 was performed on formalin-fixed paraffin-
embedded renal biopsies. For PLA2R staining, 2-mm-thick sections
were deparaffinized, hydrated, and subjected to 15min of autoclave
heating at 120 1C. The POLAP-AP system (Zytomed Systems
GmbH, Berlin, Germany) was used for detection of the primary
antibody (Atlas Antibodies). For IgG1 and IgG4 staining, the
primary antibodies (Dianova and Binding Site, respectively) were
detected by the APAAP system (Progen, Biotechnik GmbH,
Heidelberg, Germany) after pretreatment with protease (Sigma P
8038, type XXIV, Sigma-Aldrich) in 2-mm-thick sections.
Statistical analyses
For descriptive statistics, the data are presented as the means
(±s.d.). The correlation between proteinuria and PLA2R-AB
levels was analyzed by Spearman’s rank coefficient of
correlation. The differences were considered significant with
a P-value o0.05.
Isolation of mRNA from paraffin-embedded renal tissue
and measurement of PLA2R-mRNA expression by reverse
transcription-PCR
Total RNA was isolated from five 8-mm-thick sections of
formalin-fixed paraffin-embedded kidney biopsies of patients
with MN and enhanced PLA2R staining in kidney biopsies and
patients with MN and non-enhanced PLA2R staining in kidney
biopsies using the High Pure FFPE RNA Micro Kit (Roche,
Deutschland Holding GmbH, Grenzach-Wyhlen, Germany).
RNA (0.1mg) served as template for complementary DNA
synthesis using 100 ng/ml Random Hexamer Primer (Invitro-
gen, Darmstadt, Germany), 10mmol/l deoxyribonucleotide
triphosphates (Invitrogen), and 200U RevertAid Reverse
Transcriptase and an appropriate buffer (both Fermentas
GmbH, St Leon-Rot, Germany). For complementary DNA
synthesis, RNA and Primer were incubated for 5min at 65 1C.
Thereafter, 15ml enzyme–buffer–dNTP mix was added up
to a total volume of 20ml, and samples were incubated
for 10min at 25 1C, 60min at 42 1C, and finally for 10min
at 70 1C.
The relative expression of PLA2R was related to the
expression of podocin as the reference gene. For analysis, the
TaqMan gene expression assays Hs00234853_m1 (PLA2R)
and Hs00922492_m1 (podocin; Applied Biosystems, Darm-
stadt, Germany) were used. As both assays contain intron-
spanning primers, a detection of genomic DNA could be
avoided. All samples were measured in triplicates. Real-time
PCR was performed according to the protocol provided by
the manufacturer.
In vitro analysis of antibody specificity
A biochip coated with HEK 293 cells expressing the PLA2R
protein was used as described before.9,19 In the first step, the
biochip was incubated with a 1:10 dilution of a human serum
with very high levels of PLA2R-AB (titer 1:10.000). In the
second step, the biochip was incubated with the rabbit
polyclonal anti-PLA2R-AB, which was used for the immu-
nohistochemistry (Figure 4a). A biochip incubated only with
the rabbit polyclonal antibody against PLA2R, but without
human serum containing PLA2R-AB, was used as a control
(Figure 4b). Both biochips were developed with donkey
FITC-conjugated anti-rabbit IgG antibodies. These FITC-
conjugated anti-rabbit-IgG antibodies from donkey do not
bind to human PLA2R-AB as shown in Figure 4c. To verify
the binding of the human PLA2R-AB from the serum to
PLA2R, these ABs were detected with an FITC-conjugated
anti-human IgG antibody from goat (Figure 4d).
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